The FSH potencies of 12 preparations of highly purified human pituitary FSH, originating from six different laboratories, were determined by in-vivo and in-vitro The FSH potencies varied between different preparations from 827 i.u./mg to 13 100 i.u./mg by in-vivo bioassay; from 2930 to 14 600 i.u./mg by in-vitro bioassay and from 1680 to 5690 i.u./mg by immunoassay. The ratios of in-vivo biological activity relative to i n\ x=r eq-\ vitro biological activity and to immunoreactivity respectively varied between preparations from 0\m=.\06 to 2\ m=. \ 3 and from 0\m=.\15to 4\m=.\1,and there was a significant positive correlation between each of these ratios and the in-vivo biological potency of the preparations; such differences could be due to varying degrees of sialylation between preparations. On the other hand the ratios of in-vitro biological activity to immunoreactivity between preparations were fairly constant (approx. 2). The excess biological activity relative to immunoreactivity observed, in terms of the IRP, in all these materials is consistent with recent findings of some immunoreactive FSH in the IRP unassociated with biological activity. These data did not demonstrate any significant advantage, in terms of FSH in-vivo biological potency, from the use of fresh-frozen rather than acetone-dried pituitary glands for the isolation of FSH.
INTRODUCTION
Highly purified preparations of human pituitary follicle-stimulating hormone (FSH) have been isolated and characterized in a number of different laboratories (Papkoff, Mahlmann & Li, 1967; Saxena & Rathnam, 1967; Reichert, Kathan & Ryan, 1968; Roos, 1968; Peckham & Parlow, 1969; Butt & Lynch, 1974; Shownkeen, Stockell Hartree, Stewart, Mashiter & Stevens, 1976) . The data in the literature do not, however, permit a ready appreciation of the relative biological FSH potencies of these different preparations or of their relative contamination with other hormones, in particular luteinizing hormone (LH) . This is largely due to the use of different standards, frequently of ovine origin, for the estimation of their potency and of different methods for determining the protein content of such preparations (see Barker, Gray, Kennedy & Butt, 1969) ; in addition, the assay methods used for estimating LH biological activity have differed.
In the selection of material for an international reference preparation of FSH for immunoassay it has become desirable to identify FSH of the highest biological potency. We have therefore compared a number of highly purified preparations of FSH, offered to the World Health Organization (WHO) for this purpose, together with different ampouled preparations held at the National Institute for Biological Standards and Control (NIBSC) and some commercially available preparations; the 12 preparations examined originated from six different laboratories. The potencies of these materials were determined by in-vivo and in-vitro (Beaven & Holiday, 1952 
FSH assays
In-vivo bioassay The augmented ovarian weight gain assay (Steelman & Pohley, 1953) Immunoassay An equilibrium assay design described earlier was used with the anti-FSH serum provided by the WHO Matched Reagent Programme (Hall & Jeffcoate, 1977) . The cross-reactivity and specificity of this antiserum has been reported previously . Iodination was carried out by the lactoperoxidase method of Thorell & Johansson (1971) , using a highly purified FSH preparation (lot no. 19426 , Kabi Diagnostica AB; Table 1 ). The iodinated tracer was then purified by a high resolution gel filtration technique, using Ultrogel AcA-54 (LKB Produkter AB, Bromma, Sweden) (Suginami, Robertson & Diczfalusy, 1978; ). The mean index of precision from 21 multiple point assays was 0042.
LH assays
In-vivo bioassays The ovarian ascorbate depletion (Parlow, 1961) method was used. In-vitro bioassays The method of Van Damme, Robertson & Diczfalusy ( 1974) was employed. This is based on the production of testosterone by mouse Leydig cells in the presence of graded doses of LH. The mean index of precision for nine multiple point assays in this study was 0029.
Immunoassay
Details of the procedure employed in this study have been described earlier (Robertson & Diczfalusy, 1977; Suginami et al. 1978 (Thorell & Johansson, 1971 ). The iodinated hormone was then purified on Ultrogel AcA-54 in order to remove the iodinated subunits. The immunoassay was performed under equilibrium conditions. In the present study, the mean index of precision for 24 multiple point assays was 0-038.
Statistical analysis Bioassays and immunoassays were analysed as parallel-line assays (see, for example, Finney, 1978 ). An analysis of variance was performed for each assay and the assumptions of linearity and parallelism of the log dose-response curves were tested at the 5% significance level.
Logarithms of potency estimates were tested for homogeneity using a 2 test and were combined to give weighted geometric means.
RESULTS

Protein contents
Estimates of the protein content of the different preparations are given in Table 1 Roos (1968) and 6-7 by Shownkeen et al. (1976)). Table 1 ; all assays were in terms of IRP (69/104).
Contaminating activities
The LH activities of the different preparations are shown in Table 3 . The estimates of in-vivo biological potency were imprecise owing to the low sensitivity of the assays and the small amounts of material available, necessitating assays of most preparations at a single doselevel only. However, it is evident from the results obtained that the in-vivo biological activity Standardization, 1975) ) were estimated by immunoassay to be less than 20mi.u./mg for preparations A, B, C and 77/532, indicating that these preparations contained less than 0-1% (w/w) of TSH.
DISCUSSION
Comparison of FSH preparations
This study provides a more comprehensive comparison of the preparations of highly purified human pituitary FSH prepared in different laboratories than is presently available in the literature. Furthermore, the validity of the comparisons reported here is enhanced because (1) a common standard, the First International Reference Preparation, was used for all assays; (2) each type of assay was carried out in only one laboratory, eliminating interlaboratory differences in methodology; (3) the same method of protein estimation was used for all preparations.
Preparations C and 71/270 were more potent in the in-vivo FSH bioassay than the other preparations examined, with activities of the same order as those reported for the materials isolated by Roos (1968) and Peckham & Parlow (1969) . Since these preparations were isolated from acetone-dried pituitary glands in different laboratories, the results of this study do not show any significant advantage, in terms of the FSH in-vivo biological potency, from the use of fresh-frozen rather than acetone-dried pituitary glands for the isolation of FSH.
Highly purified FSH has been reported to lose in-vivo biological activity on freeze-drying (Amir, Barker, Butt & Crooke, 1966) and in particular on storage after freeze-drying (Parlow, Condliffe, Reichert & Wilhelmi, 1965 ;Papkoffe/a/. 1967; Ryan, 1968; Barker et al. 1969) ; the activity of these preparations was, however, much more stable in frozen solution (Parlow et al. 1965; Ryan, 1968; Barker et al. 1969) . In this light it is of interest that preparation C was in frozen solution. On the other hand, 71 /270 was ampouled 10 years ago, under dry nitrogen, as a freeze-dried preparation with mannitol as carrier, using procedures routinely employed for reference preparations (Campbell, 1974 ; WHO Expert Committee on Biological Standardization, 1978) , and in the assays reported here, carried out 9 years after ampouling, showed the highest in-vivo biological potency of all the preparations examined. Furthermore, the in-vivo biological potency of the FSH used in the preparation of 77/532, which was also received in frozen solution, was not reduced significantly by freezedrying during the ampouling procedure.
The contamination of these preparations with LH was in the same range as that reported for other preparations of FSH (Papkoffe/ al. 1967; Reichert et al. 1968; Peckham & Parlow, 1969; Butt & Lynch, 1974; Shownkeen et al. 1976 ). The relatively higher in-vivo than in-vitro biological activities of most of these FSH preparations are consistent with the findings of Loeber ( 1977) and a reflection of the use of ion-exchange chromatography in the isolation of FSH from LH, most of which is more basic than FSH. Thus Loeber (1977) found that LH contaminating FSH preparations was more acidic (pi 5-7-5-8) than the major LH fraction (pi 7-9-8-8) (Reichert et al. 1968; Roos, 1968; Barker et al. 1969; Saxena & Rathnam, 1971) , although both lower (Papkoff et al. 1967 ) and higher values (Shownkeen et al. 1976 ) have also been reported, and its biologically active forms exhibit charge heterogeneity (Reichert, 1971; Zaidi et al. 1981) . Desialylation reduces the in-vivo biological activity of FSH (Amir et al. 1966; Mori, 1969; Suttajit, Reichert & Winzler, 1971) but not its receptor binding activity (Reichert & Bhalla, 1974) , whereas its immunoreactivity is either unaffected (Butt & Lynch, 1968; Mori, 1969) or enhanced, in the case of urinary FSH (Vaitukaitis & Ross, 1971 ). These effects of desialylation have been attributed to the greater influence of the sialic acid of glycoproteins, such as human chorionic gonadotrophin, on their metabolism and plasma clearance, and so on their in-vivo biological activity, than on their target cell interactions (and in-vitro biological activity) and immunoreactivity (Vaitukaitis, Ross, Braunstein & Rayford 1976 On the basis of the data presented here, the most suitable material for a reference preparation for immunoassay is that with the highest specific in-vivo biological FSH activity, since the contamination of these preparations with the recognized moieties (LH and TSH) are, in all cases, too low to interfere in FSH immunoassay systems which are currently available. A high biological potency is considered, in this context, as a criterion of purity (freedom from material without FSH biological activity). The in-vivo biological activity is preferred to in-vitro biological activity for the definition of the hormone, because it has been widely used and accepted for many years and gives a measure of interactions with target cells which are in situ; the metabolic parameters, which also influence the in-vivo bioassay, are however not so relevant in the characterization of a hormone intended for use in an in-vitro (immuno-) assay.
